Business Model & Revenue
Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company headquartered in Ramat Gan, Israel, developing small molecule drugs targeting the A3 adenosine receptor (A3AR) for cancer, liver disease, and inflammatory conditions. Founded in 1994, listed on NYSE American via ADS.
Lead drug namodenoson (CF101) is an oral A3AR agonist that induces apoptosis in diseased cells via deregulation of Wnt/β-catenin, NF-κB, and RAS pathways, while showing protective effects on normal tissues via adiponectin upregulation. Second drug piclidenoson (CF102) targets psoriasis and rare genetic diseases.
Revenue model: pre-revenue clinical-stage biotech. No commercial products. Funding through equity raises and potential milestone payments from future partnerships.
Financial Highlights
Financial Metrics
| Metric | Value |
|---|---|
| Cash (FY2024) | $4.8M |
| Annual Burn | ~$7.6M |
| Estimated Runway | ~8 months |
| Total Raised (Lifetime) | ~$175M |
| Market Cap (post-surge) | ~$12M |
Pipeline
| Program | Indication | Stage | Key Status |
|---|---|---|---|
| Namodenoson | HCC | Phase III | Interim Q4 2026; Orphan Drug + Fast Track |
| Namodenoson | MASH | Phase IIb | Enrolling |
| Namodenoson | PDAC | Phase IIa | Safety endpoint met; OS/PFS maturing |
| Piclidenoson | Psoriasis | Phase III | Pivotal trial underway |
Safety Database
| Metric | Value |
|---|---|
| Patients Exposed | 1,600+ |
| Safety Profile | Clean, no significant signals |
Market Opportunity
| Indication | Market Size |
|---|---|
| Pancreatic Cancer (PDAC) | $3.7B (2025) → $6.9B (2030) |
| HCC | ~900K new cases/year globally |
| MASH | Multi-billion, emerging |
Competitive Landscape
HCC competitors: Atezolizumab (Roche) + bevacizumab, sorafenib (Bayer), lenvatinib (Eisai/Merck). No approved therapy for Child-Pugh B patients — namodenoson's target niche.
MASH competitors: Madrigal's Rezdiffra (FDA approved 2024) is first-to-market. Multiple companies pursuing follow-on approaches.
PDAC competitors: FOLFIRINOX, gemcitabine + nab-paclitaxel as standard of care. Limited effective second-line options.
A3AR as a mechanism: No other publicly traded company is pursuing A3AR agonism in oncology at clinical scale. Can-Fite's patent portfolio and 1,600-patient safety database provide meaningful first-mover advantage in this niche.
Catalysts
-
Phase III HCC interim analysis (Q4 2026). The critical make-or-break readout. Orphan Drug + Fast Track status could accelerate approval path if positive.
-
Mature PDAC OS/PFS data. Secondary endpoints (overall survival, progression-free survival) from the Phase IIa study to be presented at scientific meetings.
-
MASH Phase IIb enrollment. Steatotic liver disease is an emerging multi-billion dollar market.
-
Near-term capital raise. The company will need financing — terms and investor quality will signal market confidence.
-
Any named pharma partnership or licensing deal for the A3AR platform.
Key Risks
- Runway risk: ~8 months of cash at current burn. Dilutive financing likely before Q4 2026 HCC readout.
- Phase IIa n=20: PDAC data proves safety, not efficacy. Survival data immature and uncontrolled.
- Execution history: $175M raised historically without bringing a drug to market.
- Competition: HCC is competitive (atezolizumab, sorafenib, lenvatinib).
- Microcap volatility: 161.8x relative volume on the surge day.
- Binary Phase III risk: Failure in HCC likely wipes out equity holders.
Our Thesis
The bull case rests on namodenoson's platform potential across multiple indications. Can-Fite is running a Phase III in hepatocellular carcinoma (interim Q4 2026), a Phase IIb in MASH, and has FDA Orphan Drug + Fast Track status in HCC. The A3AR mechanism is scientifically validated — overexpressed in tumor cells vs. normal cells, enabling selective targeting with minimal toxicity. The company has documented a 9-year survival with complete cure in an advanced liver cancer patient from prior studies. If Phase III HCC shows efficacy, CANF becomes an M&A target.
The bear case: $4.8M cash vs. $7.6M annual burn = ~8 months runway. Phase IIa PDAC data (n=20) proves safety, not efficacy. The stock has ripped 80-140% on safety data; efficacy readouts are 9+ months away. If CANF can't raise capital before then, dilution is inevitable. The company has raised $175M over its lifetime without bringing a drug to market.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.